nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—Weight decreased—Capecitabine—colon cancer	0.00214	0.00214	CcSEcCtD
Anagrelide—Hypertension—Irinotecan—colon cancer	0.00213	0.00213	CcSEcCtD
Anagrelide—Pneumonia—Capecitabine—colon cancer	0.00212	0.00212	CcSEcCtD
Anagrelide—Depression—Capecitabine—colon cancer	0.0021	0.0021	CcSEcCtD
Anagrelide—Acute coronary syndrome—Capecitabine—colon cancer	0.00208	0.00208	CcSEcCtD
Anagrelide—Cerebrovascular accident—Methotrexate—colon cancer	0.00208	0.00208	CcSEcCtD
Anagrelide—Renal failure—Capecitabine—colon cancer	0.00207	0.00207	CcSEcCtD
Anagrelide—Discomfort—Irinotecan—colon cancer	0.00207	0.00207	CcSEcCtD
Anagrelide—Myocardial infarction—Capecitabine—colon cancer	0.00207	0.00207	CcSEcCtD
Anagrelide—Oedema—Vincristine—colon cancer	0.00206	0.00206	CcSEcCtD
Anagrelide—Infection—Vincristine—colon cancer	0.00205	0.00205	CcSEcCtD
Anagrelide—Urinary tract infection—Capecitabine—colon cancer	0.00205	0.00205	CcSEcCtD
Anagrelide—Conjunctivitis—Capecitabine—colon cancer	0.00205	0.00205	CcSEcCtD
Anagrelide—Convulsion—Fluorouracil—colon cancer	0.00204	0.00204	CcSEcCtD
Anagrelide—Osteoarthritis—Methotrexate—colon cancer	0.00204	0.00204	CcSEcCtD
Anagrelide—Confusional state—Irinotecan—colon cancer	0.00203	0.00203	CcSEcCtD
Anagrelide—Nervous system disorder—Vincristine—colon cancer	0.00202	0.00202	CcSEcCtD
Anagrelide—Thrombocytopenia—Vincristine—colon cancer	0.00202	0.00202	CcSEcCtD
Anagrelide—Haematuria—Capecitabine—colon cancer	0.00201	0.00201	CcSEcCtD
Anagrelide—Oedema—Irinotecan—colon cancer	0.00201	0.00201	CcSEcCtD
Anagrelide—Chest pain—Fluorouracil—colon cancer	0.00201	0.00201	CcSEcCtD
Anagrelide—Myalgia—Fluorouracil—colon cancer	0.00201	0.00201	CcSEcCtD
Anagrelide—Infection—Irinotecan—colon cancer	0.002	0.002	CcSEcCtD
Anagrelide—Hyperhidrosis—Vincristine—colon cancer	0.002	0.002	CcSEcCtD
Anagrelide—Hepatobiliary disease—Capecitabine—colon cancer	0.002	0.002	CcSEcCtD
Anagrelide—Epistaxis—Capecitabine—colon cancer	0.00199	0.00199	CcSEcCtD
Anagrelide—Discomfort—Fluorouracil—colon cancer	0.00198	0.00198	CcSEcCtD
Anagrelide—Shock—Irinotecan—colon cancer	0.00198	0.00198	CcSEcCtD
Anagrelide—Nervous system disorder—Irinotecan—colon cancer	0.00197	0.00197	CcSEcCtD
Anagrelide—Thrombocytopenia—Irinotecan—colon cancer	0.00197	0.00197	CcSEcCtD
Anagrelide—Anorexia—Vincristine—colon cancer	0.00197	0.00197	CcSEcCtD
Anagrelide—Hyperhidrosis—Irinotecan—colon cancer	0.00194	0.00194	CcSEcCtD
Anagrelide—Confusional state—Fluorouracil—colon cancer	0.00194	0.00194	CcSEcCtD
Anagrelide—Hypotension—Vincristine—colon cancer	0.00193	0.00193	CcSEcCtD
Anagrelide—Oedema—Fluorouracil—colon cancer	0.00193	0.00193	CcSEcCtD
Anagrelide—Anorexia—Irinotecan—colon cancer	0.00192	0.00192	CcSEcCtD
Anagrelide—Infection—Fluorouracil—colon cancer	0.00191	0.00191	CcSEcCtD
Anagrelide—Haemoglobin—Capecitabine—colon cancer	0.0019	0.0019	CcSEcCtD
Anagrelide—Rhinitis—Capecitabine—colon cancer	0.0019	0.0019	CcSEcCtD
Anagrelide—Haemorrhage—Capecitabine—colon cancer	0.00189	0.00189	CcSEcCtD
Anagrelide—Hepatitis—Capecitabine—colon cancer	0.00189	0.00189	CcSEcCtD
Anagrelide—Nervous system disorder—Fluorouracil—colon cancer	0.00189	0.00189	CcSEcCtD
Anagrelide—Thrombocytopenia—Fluorouracil—colon cancer	0.00189	0.00189	CcSEcCtD
Anagrelide—Hypoaesthesia—Capecitabine—colon cancer	0.00188	0.00188	CcSEcCtD
Anagrelide—Liver function test abnormal—Methotrexate—colon cancer	0.00188	0.00188	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Vincristine—colon cancer	0.00188	0.00188	CcSEcCtD
Anagrelide—Pharyngitis—Capecitabine—colon cancer	0.00188	0.00188	CcSEcCtD
Anagrelide—Tachycardia—Fluorouracil—colon cancer	0.00188	0.00188	CcSEcCtD
Anagrelide—Hypotension—Irinotecan—colon cancer	0.00188	0.00188	CcSEcCtD
Anagrelide—Urinary tract disorder—Capecitabine—colon cancer	0.00187	0.00187	CcSEcCtD
Anagrelide—Insomnia—Vincristine—colon cancer	0.00187	0.00187	CcSEcCtD
Anagrelide—Oedema peripheral—Capecitabine—colon cancer	0.00187	0.00187	CcSEcCtD
Anagrelide—Connective tissue disorder—Capecitabine—colon cancer	0.00186	0.00186	CcSEcCtD
Anagrelide—Urethral disorder—Capecitabine—colon cancer	0.00186	0.00186	CcSEcCtD
Anagrelide—Paraesthesia—Vincristine—colon cancer	0.00185	0.00185	CcSEcCtD
Anagrelide—Anorexia—Fluorouracil—colon cancer	0.00184	0.00184	CcSEcCtD
Anagrelide—Visual impairment—Capecitabine—colon cancer	0.00183	0.00183	CcSEcCtD
Anagrelide—Insomnia—Irinotecan—colon cancer	0.00182	0.00182	CcSEcCtD
Anagrelide—Paraesthesia—Irinotecan—colon cancer	0.00181	0.00181	CcSEcCtD
Anagrelide—Hypotension—Fluorouracil—colon cancer	0.0018	0.0018	CcSEcCtD
Anagrelide—Decreased appetite—Vincristine—colon cancer	0.00179	0.00179	CcSEcCtD
Anagrelide—Dyspnoea—Irinotecan—colon cancer	0.00179	0.00179	CcSEcCtD
Anagrelide—Somnolence—Irinotecan—colon cancer	0.00179	0.00179	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Vincristine—colon cancer	0.00178	0.00178	CcSEcCtD
Anagrelide—Fatigue—Vincristine—colon cancer	0.00178	0.00178	CcSEcCtD
Anagrelide—Eye disorder—Capecitabine—colon cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Dyspepsia—Irinotecan—colon cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Tinnitus—Capecitabine—colon cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Pain—Vincristine—colon cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Constipation—Vincristine—colon cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Asthma—Methotrexate—colon cancer	0.00176	0.00176	CcSEcCtD
Anagrelide—Cardiac disorder—Capecitabine—colon cancer	0.00176	0.00176	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00175	0.00175	CcSEcCtD
Anagrelide—Decreased appetite—Irinotecan—colon cancer	0.00175	0.00175	CcSEcCtD
Anagrelide—Insomnia—Fluorouracil—colon cancer	0.00174	0.00174	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Irinotecan—colon cancer	0.00174	0.00174	CcSEcCtD
Anagrelide—Fatigue—Irinotecan—colon cancer	0.00173	0.00173	CcSEcCtD
Anagrelide—Paraesthesia—Fluorouracil—colon cancer	0.00173	0.00173	CcSEcCtD
Anagrelide—Pancreatitis—Methotrexate—colon cancer	0.00173	0.00173	CcSEcCtD
Anagrelide—Pain—Irinotecan—colon cancer	0.00172	0.00172	CcSEcCtD
Anagrelide—Constipation—Irinotecan—colon cancer	0.00172	0.00172	CcSEcCtD
Anagrelide—Dyspnoea—Fluorouracil—colon cancer	0.00172	0.00172	CcSEcCtD
Anagrelide—Somnolence—Fluorouracil—colon cancer	0.00171	0.00171	CcSEcCtD
Anagrelide—Mediastinal disorder—Capecitabine—colon cancer	0.00171	0.00171	CcSEcCtD
Anagrelide—Chills—Capecitabine—colon cancer	0.0017	0.0017	CcSEcCtD
Anagrelide—Dyspepsia—Fluorouracil—colon cancer	0.00169	0.00169	CcSEcCtD
Anagrelide—Arrhythmia—Capecitabine—colon cancer	0.00169	0.00169	CcSEcCtD
Anagrelide—Abdominal discomfort—Methotrexate—colon cancer	0.00169	0.00169	CcSEcCtD
Anagrelide—Gastrointestinal pain—Vincristine—colon cancer	0.00169	0.00169	CcSEcCtD
Anagrelide—Decreased appetite—Fluorouracil—colon cancer	0.00167	0.00167	CcSEcCtD
Anagrelide—Alopecia—Capecitabine—colon cancer	0.00167	0.00167	CcSEcCtD
Anagrelide—Pancytopenia—Methotrexate—colon cancer	0.00167	0.00167	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00166	0.00166	CcSEcCtD
Anagrelide—Feeling abnormal—Irinotecan—colon cancer	0.00166	0.00166	CcSEcCtD
Anagrelide—Malnutrition—Capecitabine—colon cancer	0.00165	0.00165	CcSEcCtD
Anagrelide—Dysuria—Methotrexate—colon cancer	0.00165	0.00165	CcSEcCtD
Anagrelide—Pain—Fluorouracil—colon cancer	0.00165	0.00165	CcSEcCtD
Anagrelide—Gastrointestinal pain—Irinotecan—colon cancer	0.00164	0.00164	CcSEcCtD
Anagrelide—Abdominal pain—Vincristine—colon cancer	0.00163	0.00163	CcSEcCtD
Anagrelide—Body temperature increased—Vincristine—colon cancer	0.00163	0.00163	CcSEcCtD
Anagrelide—Flatulence—Capecitabine—colon cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Erectile dysfunction—Methotrexate—colon cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Photosensitivity reaction—Methotrexate—colon cancer	0.00161	0.00161	CcSEcCtD
Anagrelide—Back pain—Capecitabine—colon cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Body temperature increased—Irinotecan—colon cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Abdominal pain—Irinotecan—colon cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Feeling abnormal—Fluorouracil—colon cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Muscle spasms—Capecitabine—colon cancer	0.00158	0.00158	CcSEcCtD
Anagrelide—Pneumonia—Methotrexate—colon cancer	0.00158	0.00158	CcSEcCtD
Anagrelide—Depression—Methotrexate—colon cancer	0.00157	0.00157	CcSEcCtD
Anagrelide—Vision blurred—Capecitabine—colon cancer	0.00155	0.00155	CcSEcCtD
Anagrelide—Renal failure—Methotrexate—colon cancer	0.00154	0.00154	CcSEcCtD
Anagrelide—Ill-defined disorder—Capecitabine—colon cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Urticaria—Fluorouracil—colon cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Conjunctivitis—Methotrexate—colon cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Anaemia—Capecitabine—colon cancer	0.00152	0.00152	CcSEcCtD
Anagrelide—Body temperature increased—Fluorouracil—colon cancer	0.00152	0.00152	CcSEcCtD
Anagrelide—Sweating—Methotrexate—colon cancer	0.00151	0.00151	CcSEcCtD
Anagrelide—Haematuria—Methotrexate—colon cancer	0.0015	0.0015	CcSEcCtD
Anagrelide—Malaise—Capecitabine—colon cancer	0.00149	0.00149	CcSEcCtD
Anagrelide—Hepatobiliary disease—Methotrexate—colon cancer	0.00149	0.00149	CcSEcCtD
Anagrelide—Epistaxis—Methotrexate—colon cancer	0.00148	0.00148	CcSEcCtD
Anagrelide—Asthenia—Vincristine—colon cancer	0.00148	0.00148	CcSEcCtD
Anagrelide—Syncope—Capecitabine—colon cancer	0.00148	0.00148	CcSEcCtD
Anagrelide—Palpitations—Capecitabine—colon cancer	0.00146	0.00146	CcSEcCtD
Anagrelide—Loss of consciousness—Capecitabine—colon cancer	0.00145	0.00145	CcSEcCtD
Anagrelide—Asthenia—Irinotecan—colon cancer	0.00144	0.00144	CcSEcCtD
Anagrelide—Cough—Capecitabine—colon cancer	0.00144	0.00144	CcSEcCtD
Anagrelide—Hypertension—Capecitabine—colon cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Haemoglobin—Methotrexate—colon cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Diarrhoea—Vincristine—colon cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Haemorrhage—Methotrexate—colon cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Hepatitis—Methotrexate—colon cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Myalgia—Capecitabine—colon cancer	0.0014	0.0014	CcSEcCtD
Anagrelide—Chest pain—Capecitabine—colon cancer	0.0014	0.0014	CcSEcCtD
Anagrelide—Arthralgia—Capecitabine—colon cancer	0.0014	0.0014	CcSEcCtD
Anagrelide—Pharyngitis—Methotrexate—colon cancer	0.0014	0.0014	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Urinary tract disorder—Methotrexate—colon cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Discomfort—Capecitabine—colon cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Urethral disorder—Methotrexate—colon cancer	0.00138	0.00138	CcSEcCtD
Anagrelide—Diarrhoea—Irinotecan—colon cancer	0.00138	0.00138	CcSEcCtD
Anagrelide—Dry mouth—Capecitabine—colon cancer	0.00137	0.00137	CcSEcCtD
Anagrelide—Dizziness—Vincristine—colon cancer	0.00137	0.00137	CcSEcCtD
Anagrelide—Pruritus—Fluorouracil—colon cancer	0.00136	0.00136	CcSEcCtD
Anagrelide—Visual impairment—Methotrexate—colon cancer	0.00136	0.00136	CcSEcCtD
Anagrelide—Confusional state—Capecitabine—colon cancer	0.00136	0.00136	CcSEcCtD
Anagrelide—Oedema—Capecitabine—colon cancer	0.00135	0.00135	CcSEcCtD
Anagrelide—Infection—Capecitabine—colon cancer	0.00134	0.00134	CcSEcCtD
Anagrelide—Dizziness—Irinotecan—colon cancer	0.00133	0.00133	CcSEcCtD
Anagrelide—Shock—Capecitabine—colon cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Nervous system disorder—Capecitabine—colon cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Eye disorder—Methotrexate—colon cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Diarrhoea—Fluorouracil—colon cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Thrombocytopenia—Capecitabine—colon cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Tinnitus—Methotrexate—colon cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Tachycardia—Capecitabine—colon cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Vomiting—Vincristine—colon cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Cardiac disorder—Methotrexate—colon cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Skin disorder—Capecitabine—colon cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Rash—Vincristine—colon cancer	0.0013	0.0013	CcSEcCtD
Anagrelide—Hyperhidrosis—Capecitabine—colon cancer	0.0013	0.0013	CcSEcCtD
Anagrelide—Dermatitis—Vincristine—colon cancer	0.0013	0.0013	CcSEcCtD
Anagrelide—Headache—Vincristine—colon cancer	0.00129	0.00129	CcSEcCtD
Anagrelide—Anorexia—Capecitabine—colon cancer	0.00128	0.00128	CcSEcCtD
Anagrelide—Vomiting—Irinotecan—colon cancer	0.00128	0.00128	CcSEcCtD
Anagrelide—Dizziness—Fluorouracil—colon cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Mediastinal disorder—Methotrexate—colon cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Rash—Irinotecan—colon cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Dermatitis—Irinotecan—colon cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Chills—Methotrexate—colon cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Headache—Irinotecan—colon cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Hypotension—Capecitabine—colon cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Alopecia—Methotrexate—colon cancer	0.00125	0.00125	CcSEcCtD
Anagrelide—Malnutrition—Methotrexate—colon cancer	0.00123	0.00123	CcSEcCtD
Anagrelide—Nausea—Vincristine—colon cancer	0.00123	0.00123	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00123	0.00123	CcSEcCtD
Anagrelide—Vomiting—Fluorouracil—colon cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Insomnia—Capecitabine—colon cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Rash—Fluorouracil—colon cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Dermatitis—Fluorouracil—colon cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Paraesthesia—Capecitabine—colon cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Headache—Fluorouracil—colon cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Dyspnoea—Capecitabine—colon cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Nausea—Irinotecan—colon cancer	0.00119	0.00119	CcSEcCtD
Anagrelide—Back pain—Methotrexate—colon cancer	0.00119	0.00119	CcSEcCtD
Anagrelide—Dyspepsia—Capecitabine—colon cancer	0.00118	0.00118	CcSEcCtD
Anagrelide—Decreased appetite—Capecitabine—colon cancer	0.00117	0.00117	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Capecitabine—colon cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Fatigue—Capecitabine—colon cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Vision blurred—Methotrexate—colon cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Pain—Capecitabine—colon cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Constipation—Capecitabine—colon cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Nausea—Fluorouracil—colon cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—colon cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Anaemia—Methotrexate—colon cancer	0.00113	0.00113	CcSEcCtD
Anagrelide—Feeling abnormal—Capecitabine—colon cancer	0.00111	0.00111	CcSEcCtD
Anagrelide—Malaise—Methotrexate—colon cancer	0.00111	0.00111	CcSEcCtD
Anagrelide—Gastrointestinal pain—Capecitabine—colon cancer	0.0011	0.0011	CcSEcCtD
Anagrelide—Cough—Methotrexate—colon cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Urticaria—Capecitabine—colon cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Abdominal pain—Capecitabine—colon cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Body temperature increased—Capecitabine—colon cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Convulsion—Methotrexate—colon cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Discomfort—Methotrexate—colon cancer	0.00103	0.00103	CcSEcCtD
Anagrelide—Confusional state—Methotrexate—colon cancer	0.00101	0.00101	CcSEcCtD
Anagrelide—Infection—Methotrexate—colon cancer	0.000995	0.000995	CcSEcCtD
Anagrelide—Nervous system disorder—Methotrexate—colon cancer	0.000982	0.000982	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—colon cancer	0.000981	0.000981	CcSEcCtD
Anagrelide—Skin disorder—Methotrexate—colon cancer	0.000973	0.000973	CcSEcCtD
Anagrelide—Hyperhidrosis—Methotrexate—colon cancer	0.000968	0.000968	CcSEcCtD
Anagrelide—Asthenia—Capecitabine—colon cancer	0.000965	0.000965	CcSEcCtD
Anagrelide—Anorexia—Methotrexate—colon cancer	0.000955	0.000955	CcSEcCtD
Anagrelide—Pruritus—Capecitabine—colon cancer	0.000952	0.000952	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—colon cancer	0.000936	0.000936	CcSEcCtD
Anagrelide—Diarrhoea—Capecitabine—colon cancer	0.000921	0.000921	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000913	0.000913	CcSEcCtD
Anagrelide—Insomnia—Methotrexate—colon cancer	0.000906	0.000906	CcSEcCtD
Anagrelide—Paraesthesia—Methotrexate—colon cancer	0.000899	0.000899	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—colon cancer	0.000893	0.000893	CcSEcCtD
Anagrelide—Somnolence—Methotrexate—colon cancer	0.00089	0.00089	CcSEcCtD
Anagrelide—Dizziness—Capecitabine—colon cancer	0.00089	0.00089	CcSEcCtD
Anagrelide—Dyspepsia—Methotrexate—colon cancer	0.000882	0.000882	CcSEcCtD
Anagrelide—Decreased appetite—Methotrexate—colon cancer	0.000871	0.000871	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000865	0.000865	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—colon cancer	0.000864	0.000864	CcSEcCtD
Anagrelide—Pain—Methotrexate—colon cancer	0.000857	0.000857	CcSEcCtD
Anagrelide—Vomiting—Capecitabine—colon cancer	0.000855	0.000855	CcSEcCtD
Anagrelide—Rash—Capecitabine—colon cancer	0.000848	0.000848	CcSEcCtD
Anagrelide—Dermatitis—Capecitabine—colon cancer	0.000848	0.000848	CcSEcCtD
Anagrelide—Headache—Capecitabine—colon cancer	0.000843	0.000843	CcSEcCtD
Anagrelide—Feeling abnormal—Methotrexate—colon cancer	0.000825	0.000825	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methotrexate—colon cancer	0.000819	0.000819	CcSEcCtD
Anagrelide—Nausea—Capecitabine—colon cancer	0.000799	0.000799	CcSEcCtD
Anagrelide—Urticaria—Methotrexate—colon cancer	0.000796	0.000796	CcSEcCtD
Anagrelide—Abdominal pain—Methotrexate—colon cancer	0.000792	0.000792	CcSEcCtD
Anagrelide—Body temperature increased—Methotrexate—colon cancer	0.000792	0.000792	CcSEcCtD
Anagrelide—Asthenia—Methotrexate—colon cancer	0.000719	0.000719	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—colon cancer	0.000709	0.000709	CcSEcCtD
Anagrelide—Diarrhoea—Methotrexate—colon cancer	0.000685	0.000685	CcSEcCtD
Anagrelide—Dizziness—Methotrexate—colon cancer	0.000662	0.000662	CcSEcCtD
Anagrelide—Vomiting—Methotrexate—colon cancer	0.000637	0.000637	CcSEcCtD
Anagrelide—Rash—Methotrexate—colon cancer	0.000632	0.000632	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—colon cancer	0.000631	0.000631	CcSEcCtD
Anagrelide—Headache—Methotrexate—colon cancer	0.000627	0.000627	CcSEcCtD
Anagrelide—Nausea—Methotrexate—colon cancer	0.000595	0.000595	CcSEcCtD
